Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
August 28 2024 - 8:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that members of management will participate in the
following upcoming investor conferences:
- 2024 Wells Fargo
Healthcare Conference: Fireside chat on Wednesday, September 4 at
3:45 p.m. ET.
- Morgan Stanley 22nd
Annual Global Healthcare Conference: Fireside chat on Friday,
September 6 at 10:00 a.m. ET.
- H.C. Wainwright 25th Annual Global
Investment Conference: Fireside chat on Wednesday, September 11 at
11:30 a.m. ET.
A live webcast of these events, as well as archived recordings,
will be available on Avadel’s Investor Relations website,
investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to
transform lives. Our approach includes applying innovative
solutions to the development of medications that address the
challenges patients face with current treatment options. Avadel’s
commercial product, LUMRYZ™, was approved by the U.S. Food
& Drug Administration (FDA) as the first and only
once-at-bedtime oxybate for the treatment of cataplexy or excessive
daytime sleepiness (EDS) in adults with narcolepsy. For more
information, please visit www.avadel.com.
Investor Contact:Courtney MogerleyPrecision
AQCourtney.Mogerley@precisionAQ.com(212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com (609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Nov 2023 to Nov 2024